Biovitrum: A New Flavor of Spin-Off

Pharmacia spin-off Biovitrum, like other biotechs born out of Big Pharma, has found favor with investors seeking experienced management and advanced programs. But Biovitrum's size, cash flow, and independence appear to make it more attractive still.

More from Global Vision

More from In Vivo